Equity Profile

ACAD

ACADIA Pharmaceuticals Inc.

Health CareBiotechnology$3.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, which is vital for future success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACAD Q2-2026 Earnings Preview

Context

Company Snapshot

ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders. With a market cap of $4 billion, its work is crucial as it addresses significant unmet medical needs in the healthcare sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+226.66%

Avg Stock Reaction

+1.25%

Last Quarter Recap

In Q1 2026, ACADIA reported an EPS of $0.02, falling short of the expected $0.04, leading to a stock decline of 3.89% the following day. The company has shown a strong history of beating earnings estimates in previous quarters.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for ACADIA's upcoming earnings are mixed, given the recent earnings miss and the lack of analyst estimates. Investors will be looking for signs of recovery and growth.

Bull Case

The optimistic view hinges on the potential for ACADIA to exceed earnings expectations, leveraging its strong history of beating estimates and demonstrating significant revenue growth.

Bear Case

On the pessimistic side, concerns about the company's ability to maintain profitability and the impact of recent insider selling could weigh heavily on investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will ACADIA report an EPS that meets or exceeds the previous quarter's expectations?

Given the recent miss, a strong EPS performance is crucial for restoring investor confidence and demonstrating operational stability.

What insights will management provide regarding revenue growth and future product pipeline?

Investors are keen to understand the company's growth trajectory and potential market opportunities, which could significantly influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ACADIA's potential for recovery based on its strong history of beating earnings expectations, despite the recent miss.

Supporting Evidence

ACADIA has an 88% EPS beat rate over the last eight quarters, indicating a strong track record.

The options market is pricing a 10.63% move, which is significantly higher than the historical average of 2.23%, suggesting heightened expectations.

Insider selling could be a temporary concern, but it does not necessarily reflect the company's long-term growth potential.

Key Risk

If ACADIA reports an EPS significantly above $0.02, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a disappointing earnings report, and investors are looking for signs of recovery.

Bull Confirmed If

A reported EPS of $0.04 or higher would confirm the bull case and restore confidence in ACADIA's growth potential.

Bear Confirmed If

An EPS below $0.02 would reinforce concerns about the company's profitability and future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±10.63%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.6% while ACAD has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.8%

Calls (134K)P/C Ratio: 0.05Puts (500)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$690,249.35

31,986 sh

5 insiders

Net

$690,249.35

Net selling

Most Active Insiders· 11 open-market trades

EVP, CHIEF FINANCIAL OFFICERSchneyer Mark C.
$219,275.68

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ACADIA beats expectations, history suggests a positive reaction, with an average 1-day move of +1.98%, confirming the company's growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance from management.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of -3.89% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming clinical trials.
2Management's commentary on revenue growth and market expansion strategies.
3Insights into the impact of recent insider selling on company strategy.
4Details on cost management and operational efficiency improvements.
5Guidance on future earnings expectations and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, which is vital for future success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACAD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+226.66%

Avg Stock Reaction

+1.25%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for ACADIA's upcoming earnings are mixed, given the recent earnings miss and the lack of analyst estimates. Investors will be looking for signs of recovery and growth.

Bull Case

The optimistic view hinges on the potential for ACADIA to exceed earnings expectations, leveraging its strong history of beating estimates and demonstrating significant revenue growth.

Bear Case

On the pessimistic side, concerns about the company's ability to maintain profitability and the impact of recent insider selling could weigh heavily on investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will ACADIA report an EPS that meets or exceeds the previous quarter's expectations?

Given the recent miss, a strong EPS performance is crucial for restoring investor confidence and demonstrating operational stability.

What insights will management provide regarding revenue growth and future product pipeline?

Investors are keen to understand the company's growth trajectory and potential market opportunities, which could significantly influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ACADIA's potential for recovery based on its strong history of beating earnings expectations, despite the recent miss.

Supporting Evidence

ACADIA has an 88% EPS beat rate over the last eight quarters, indicating a strong track record.

The options market is pricing a 10.63% move, which is significantly higher than the historical average of 2.23%, suggesting heightened expectations.

Insider selling could be a temporary concern, but it does not necessarily reflect the company's long-term growth potential.

Key Risk

If ACADIA reports an EPS significantly above $0.02, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a disappointing earnings report, and investors are looking for signs of recovery.

Bull Confirmed If

A reported EPS of $0.04 or higher would confirm the bull case and restore confidence in ACADIA's growth potential.

Bear Confirmed If

An EPS below $0.02 would reinforce concerns about the company's profitability and future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±10.63%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.6% while ACAD has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.8%

Calls (134K)P/C Ratio: 0.05Puts (500)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$690,249.35

31,986 sh

5 insiders

Net

$690,249.35

Net selling

Most Active Insiders· 11 open-market trades

EVP, CHIEF FINANCIAL OFFICERSchneyer Mark C.
$219,275.68

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ACADIA beats expectations, history suggests a positive reaction, with an average 1-day move of +1.98%, confirming the company's growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance from management.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of -3.89% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming clinical trials.
2Management's commentary on revenue growth and market expansion strategies.
3Insights into the impact of recent insider selling on company strategy.
4Details on cost management and operational efficiency improvements.
5Guidance on future earnings expectations and market conditions.